Navigation Links
Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
Date:1/12/2009

icated:

  • Results with R7128 500mg bid, 1000mg bid and 1500mg bid with SOC achieved a mean 3.8 log10 IU/mL (30% RVR, 6 of 20), 5.0 log10 IU/mL (88% RVR, 22 of 25) and 5.1 log10 IU/mL (85% RVR, 17 of 20) decrease in HCV RNA, respectively. Results with placebo with SOC indicated patients achieved a mean 2.9 log10 IU/mL decrease in HCV RNA and 18.75% (3 of 16) patients achieved RVR (<15 IU/ml).

In a harder to treat, non-responder, genotype 2 and 3 HCV patient population treated for 4 weeks:

  • Results with R7128 1500mg bid with SOC led to 90% of patients achieving an RVR (<15 IU/ml) compared to 60% in the standard of care arm.

In November 2008, Pharmasset, Roche and InterMune initiated the INFORM-1 trial to investigate the combination of R7128 with InterMune's R7227 (ITMN-191), a protease inhibitor in HCV patients in the absence of pegylated interferon and ribavirin. Patients will receive a maximum of 14 days of combination treatment, followed by Pegasys(R) plus Copegus(R) for a further 46 weeks. The aim of the study is to investigate the safety and antiviral activity of the combination.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmasset to Present at Two Upcoming Investor Conferences
2. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
3. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
4. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
5. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
6. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
7. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
8. Pharmasset Joins Russell 3000 Index
9. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
10. Pharmasset Selected to Join the NASDAQ Biotechnology Index
11. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... (PRWEB) March 05, 2015 BioPlus Specialty ... the position of Vice President of Managed Care. In ... relationships for one of the nation’s leading specialty pharmacies. ... than 15 years of specialty pharmacy and biotech experience ... with Raptor Pharmaceuticals, Vertex Pharmaceuticals, and Pfizer. Prior to ...
(Date:3/5/2015)... SAN DIEGO and TORONTO ... APTO, TSX: APS), a clinical-stage company developing new therapeutics ... cancer, today announced that William G. Rice , ... at the upcoming 27th Annual ROTH Conference on Tuesday, ... the The Ritz Carlton, Laguna Niguel, CA. ...
(Date:3/5/2015)... , March 5, 2015  In response to ... Miami, FL on February 12, ... both of strong financial health and their SUDOSCAN® devices ... research has indicated. Furthermore, Impeto prefers to have the courts ... There are more than 40 articles written by Key ...
(Date:3/5/2015)... 2015 RMI specializes ... orthopedic conditions such as meniscal tears, ACL injuries, ... joint pain due to degenerative conditions like osteoarthritis. ... surgeries to promote better post-surgical outcomes. , Stemnexa ... pain-free bone marrow harvesting with two complimentary cellular ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5
... Ltd. (NYSE Amex:, SVA ), a leading developer and provider of ... and twelve month,periods ended December 31, 2008. , , ... 2008 sales increasing 39% year-over-year to $46.5, ... in 2008, up from 5.12 million in, ...
... Biotech Ltd. (NYSE Amex:, SVA ), a leading developer and provider ... three and twelve month,periods ended December 31, 2008. , , ... year 2008 sales increasing 39% year-over-year to $46.5, ... Healive(R) in 2008, up from 5.12 million in, ...
... CPHD ) today announced that it will report ... 2009, on Thursday, April 23, 2009, after the close of ... p.m. Pacific Time on Thursday, April 23, 2009, to discuss ... Cepheid,s website at www.cepheid.com/investors at least ...
Cached Biology Technology:Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 2Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 3Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 4Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 5Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 6Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 7Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 8Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 9Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 10Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 11Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 12Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 13Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 14Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 15Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 16Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 17Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 18Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 2Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 3Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 4Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 5Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 6Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 7Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 8Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 9Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 10Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 11Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 12Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 13Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast 2
(Date:2/5/2015)... Conn. , Jan. 26, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... new corporate website ( http://www.nxt-id.com/ ) as part of ... smart wallet. The Company launched its new consumer website ... Gino Pereira , CEO of NXT-ID said, "Our new ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
(Date:2/5/2015)... 3, 2015 Despite a lack of ... such as consumer electronics, automotive, storage and telecommunication ... technology (SMT) screen printers. Innovations in electronics and ... push the adoption curve up. Meanwhile, sale volumes ... glue dispensers are indispensable in the production of ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... Hundreds of years ago, humans discovered flammable gas could ... process called anaerobic digestion. Today, EU laws are pushing governments ... into compost to enrich soil or biogas for energy. Our ... up being dumped in diminishing landfill sites. However, while ...
... Editor in Chief of the #1 ranked journal in robotics*, ... the announcement made by President Obama to spend $70 million ... in Chief since 2000, said "The US National Robotics Initiative ... of the many areas that robotics impacts. Surgical robots, autonomous ...
... world,s largest database on plants, functional properties, or ... traits for 69,000 out of the world,s 300,000 ... collaboration of scientists from 106 re-search institutions. The ... Max Planck Institute for Biogeochemistry in Jena (Germany). ...
Cached Biology News:Time to make more out of waste 2Time to make more out of waste 3Editor-in-chief of leading robotics journal responds to Obama's robotics initiative 2Global plant database set to promote biodiversity research and Earth-system sciences 2